This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

"You Can't Sequester Cancer" Argue Ex-House Aging Committee Director Robert Weiner And GWU Professor Patricia Berg In Today's Washington Times Following Rally With Thousands Of Scientists

WASHINGTON, April 11, 2013 /PRNewswire-USNewswire/ -- Former House Aging Committee Director Robert Weiner and George Washington University Professor Dr. Patricia Berg, a GWU Medical Center cancer laboratory director, make the case that "You can't sequester cancer. You can only hurt the research that treats and prevents it, and stop the treatments themselves."  In an article in today's Washington Times, Weiner and Berg say, "That is the message of 18,000 scientists gathered for the American Association for Cancer Research's annual convention this week in Washington."

Weiner and Berg say, "Those thousands of scientists-- usually wonky researchers poring over their microscopes -- held a 'Rally for Medical Research' on the grounds of the Carnegie Library across from the Washington Convention Center. In rhythm to drumbeats, the scientists became political advocates as they chanted after each speaker, 'More Progress! More Hope! More Life!'"

Argue Weiner and Berg: "Cancer is neither Democratic nor Republican. 1.6 million people a year get it, according to the National Institutes for Health. 40,000 women each year die from breast cancer alone. Cancer mortality -- to be clear, that means the number who die from the disease -- has been reduced by one-third over the past three decades-- largely from the research that has produced new drugs, treatments, prevention strategies, and knowledge about better diet and living habits. Still, one of two men, and one of three women, will contract cancer sometime in their lives, and then becomes subject to 'the vortex of disbelief and fear,' as one speaker explained."

The authors contend, "When we sequester the research -- stop it dead in its tracks so no additional advances can be made by scientists who are on the cutting edge -- we are cutting off our nose to spite our face."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs